Xencor company info

What does Xencor do?
Xencor (NASDAQ:XNCR) focuses on developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma, and allergic diseases. The company's technology platform is designed to improve the function and clinical utility of antibody therapeutics. Xencor’s pipeline includes novel antibody candidates currently in clinical development, aimed at providing new treatment options for patients in need. With a commitment to innovation, Xencor's objective is to leverage its XmAb® technology platform to create and develop advanced therapeutic antibodies that can potentially transform the way diseases are treated.
Xencor company media
Company Snapshot

Is Xencor a public or private company?

key
Ownership
Public

How many people does Xencor employ?

people
Employees
285

What sector is Xencor in?

pie chart
Sector
Health Care

Where is the head office for Xencor?

location pin
Head Office
California, United States

What year was Xencor founded?

founded flag
Year Founded
1997
What does Xencor specialise in?
/Monoclonal Antibodies /Protein Therapeutics /Cancer Treatments /Autoimmune Diseases /Biosimilars Development /Antibody Technology

What are the products and/or services of Xencor?

Overview of Xencor offerings
XmAb antibody engineering platform, a suite of technologies for improving antibody drug properties.
Tidutamab, an investigational bispecific antibody targeting CD3 and solid tumor antigen for cancer therapy.
Plamotamab, a CD20 x CD3 bispecific antibody designed for the treatment of B-cell malignancies.
Vibecotamab, a bispecific antibody targeting CD123 and CD3 for acute myeloid leukemia.
Obexelimab, designed to target B-cell signaling for autoimmune diseases.
XmAb717, an innovative bispecific antibody for the treatment of various cancers.

Who is in the executive team of Xencor?

Xencor leadership team
  • Dr. Bassil I. Dahiyat Ph.D.
    Dr. Bassil I. Dahiyat Ph.D.
    Co-Founder, CEO, President & Director
  • Dr. John R. Desjarlais Ph.D.
    Dr. John R. Desjarlais Ph.D.
    Executive VP of Research & Chief Scientific Officer
  • Ms. Celia E. Eckert J.D.
    Ms. Celia E. Eckert J.D.
    Senior VP, General Counsel & Corporate Secretary
  • Dr. Nancy  Valente M.D.
    Dr. Nancy Valente M.D.
    Executive VP & Chief Development Officer
  • Mr. Bart  Cornelissen
    Mr. Bart Cornelissen
    Senior VP & CFO
  • Mr. Charles  Liles
    Mr. Charles Liles
    Associate Director and Head of Corporate Communications & Investor Relations
  • Ms. Jennifer  Sandoz
    Ms. Jennifer Sandoz
    Vice President of Human Resources
  • Dr. Jeremy  Grunstein Ph.D.
    Dr. Jeremy Grunstein Ph.D.
    Senior Vice President of Business Development